Anti‐inflammatory effects of nitric oxide‐releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis

Abstract

The concept that nitric oxide (NO) release can be beneficial in inflammatory conditions has raised more attention in the recent years, particularly with the development of nitric oxide‐releasing anti‐inflammatory drugs. There is considerable evidence that NO is capable of enhancing the anti‐inflammatory benefits of conventional anti‐inflammatory drugs. Since hydrocortisone is the most widely used anti‐inflammatory drug for the treatment of skin inflammation, we compared the anti‐inflammatory effects of hydrocortisone to an NO‐releasing derivative of hydrocortisone, NCX 1022, in a murine model of irritant contact dermatitis, induced by epidermal application of benzalkonium chloride. Topical pre‐ and post‐treatment with NCX 1022 (3 nmol) in C57BL6 mice not only reduced ear oedema formation in a dose‐dependent manner, but also was significantly more effective than the parent compound during the initial stages of inflammation (from 1 to 5 h). NCX 1022, but not hydrocortisone, significantly inhibited granulocyte recruitment (tissue myeloperoxidase activity). Histological samples of mouse ears treated with NCX 1022 showed significant reduction in both the number of infiltrated cells and disruption of the tissue architecture compared to hydrocortisone‐treated tissues. With intravital microscopy, we observed that both pre‐ and post‐treatments with NCX 1022 were more effective than hydrocortisone in terms of inhibiting benzalkonium chloride‐induced leukocyte adhesion to the endothelium, without affecting the flux of rolling leukocytes or venule diameter. These results suggest that by releasing NO, NCX 1022 modulates one of the early events of skin inflammation: the recruitment of leukocytes to the site of inflammation. Overall, we have shown that NO‐hydrocortisone provided faster and greater protective effects, reducing major inflammatory parameters (leukocyte adhesion and recruitment, oedema formation, tissue disruption) compared to its parental compound. British Journal of Pharmacology (2004) 143, 618–625. doi:

Dietary fish oil n−3 fatty acids increase regulatory cytokine production and exert anti‐inflammatory effects in two murine models of inflammation

“…Although there are limitations in the use of this model for inflammatory reactions, it is one approach for studying the initial phase of inflammation (46) and could give some clues about the anti-inflammatory potential of n-3 PUFA. In this model, weight and water content of irritated ears was lower in FO-fed mice, suggesting that vasodilatation and edema had been less drastic.…”

Anti-inflammatory glucocorticoid drugs: reflections after 60 years

“…donating nitric oxide. Such nitrosteroids have shown potent anti-inflammatory activity with less damage to bone (Paul-Clark et al 2006) or skin (Hyun et al 2004).…”

Effect of Skin Sensitizers on Inducible Nitric Oxide Synthase Expression and Nitric Oxide Production in Skin Dendritic Cells: Role of Different Immunosuppressive Drugs

“…However, the mechanism by which NO acts in ACD remains elusive (26,36) . Hyun et al (37) demonstrated that in a murine model of contact dermatitis, NO-releasing hydrocortisone NCX 1022 provided faster and greater protective effects than hydrocortisone alone. However, the researchers suggested that NO exerts a dual role in ACD, exerting both beneficial and aggravating effects (27) .…”